Agilent Technologies to acquire Biocare Medical in $950m deal

Agilent Technologies has agreed to get pathology solutions supplier Biocare Medical successful a currency transaction worthy $950m.

The acquisition volition springiness beingness sciences steadfast Agilent power of California-based Biocare’s immunohistochemistry (IHC), successful situ hybridisation (ISH) and fluorescence successful situ hybridisation (FISH) solutions that are designed to enactment improved diligent wellness outcomes crossed oncology and broader objective pathology.

With entree to these products, Agilent highlighted that it expects the operation of its planetary operations with Biocare’s US commercialized beingness to make a stronger level to amended service a “broader base” of probe and objective customers.

Given that Biocare holds much than 300 specialised antibodies, Agilent added that it besides anticipates the acquisition to grow its quality to make and commercialise caller successful vitro diagnostic (IVD) antibodies.

Agilent expects the transaction to adjacent by the 4th fourth of its 2026 fiscal twelvemonth and go accretive to its net per stock (EPS) astir 12 months pursuing close. Once the transaction completes, Biocare volition go portion of Agilent’s Life Sciences and Diagnostics Markets Group (LDG) concern segment.

In Q1 of fiscal twelvemonth 2026, Agilent’s LDG concern generated gross of $679m, indicative of 5% maturation year-over-year (YoY).

Agilent CEO Padraig McDonnell said the acquisition of Biocare would heighten the company’s pathology portfolio, with the determination resonating with the company’s strategy to “drive semipermanent maturation done customer-centric innovation and disciplined superior allocation”.

“Together, this complementary operation volition alteration america to amended service our valued pathology customers crossed objective and probe settings, accelerate innovation and enactment semipermanent worth instauration for our shareholders,” McDonnell continued.

Biocare has been nether the stewardship of VC firms Excellere Partners and GHO Capital since 2021, having experienced consecutive double-digit maturation since the VC firms became the company’s cardinal investors. In 2025, the institution generated gross of $90m.

Biocare CEO Luiz de Luzuriaga commented: “After years of important progress, this is the close clip to determination guardant with caller ownership aligned with our committedness to merchandise quality, objective interaction and worth creation.”

Should Agilent’s statement to get Biocare spell ahead, it volition signify the company’s 2nd big-money acquisition successful arsenic galore years. In September 2024, Agilent completed the $925m acquisition of Canadian declaration improvement and manufacturing organisation (CDMO) BIOVECTRA.